Several pieces of evidence demonstrated that inhibiting IDO will reduce Kyn/AhR-mediated Treg differentiation, providing an effective strategy for the prevention and treatment of inflammation-related colon cancer, and has reference value for the treatment of GC [79]. This evidence concerns the gene IDO1 and gastric cancer.